Clinical Scorecard: Rethinking Cyclophotocoagulation in Refractory Glaucoma
At a Glance
| Category | Detail |
|---|---|
| Condition | Refractory Glaucoma |
| Key Mechanisms | Cyclophotocoagulation (CPC) reduces intraocular pressure through targeted laser treatment of the ciliary body. |
| Target Population | Patients with refractory glaucoma who may not respond to minimally invasive glaucoma surgeries (MIGS). |
| Care Setting | Ophthalmology clinics and surgical centers. |
Key Highlights
- CPC is nonincisional, reducing risks of infection and bleeding.
- Fewer postoperative visits required compared to trabeculectomies and tube surgeries.
- Recovery time is significantly shorter with CPC.
- CPC shows comparable efficacy and risk profiles to traditional glaucoma surgeries.
- Micropulse CPC has similar efficacy but lower inflammation and pain.
Guideline-Based Recommendations
Diagnosis
- Consider CPC for eyes with truly refractory glaucoma.
Management
- Utilize CPC as an alternative to trabeculectomy or tube surgery in appropriate patients.
Monitoring & Follow-up
- Monitor intraocular pressure and visual acuity postoperatively.
Risks
- Evaluate ocular factors such as prior surgeries and active rubeosis before choosing CPC.
Patient & Prescribing Data
Patients with a history of multiple eye surgeries or those with social or physical limitations.
CPC is easier for patients with difficulties lying flat or accessing transportation for follow-up visits.
Clinical Best Practices
- Consider patient-specific factors when recommending CPC.
- Educate patients about the benefits and risks of CPC compared to traditional surgeries.
- Utilize micropulse CPC for patients at higher risk of inflammation.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
